Informations générales (source: ClinicalTrials.gov)
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE (TEC-CARE)
Observational
Intergroupe Francophone du Myelome (Voir sur ClinicalTrials)
septembre 2023
septembre 2026
24 mai 2025
200 adult patients with multiple myeloma receiving teclistamb will be included.
Effectiveness, safety, and condition of use of teclistamab in early access program
(post-MA) will be assessed. Primary objective is the evaluation of overall response rate
(ORR) of teclistamab according to IMWG criteria.
This is a multicenter, prospective, observational study.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | BENRAMDANE | 14/02/2025 09:03:21 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Necker-Enfants Malades | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Henri Becquerel - Rouen - France | Contact (sur clinicalTrials) | ||||
| Centre hospitalier d'Argenteuil - Argenteuil - France | Contact (sur clinicalTrials) | ||||
| Centre hospitalier de Brive-la-Gaillarde - Brive-la-Gaillarde - France | Contact (sur clinicalTrials) | ||||
| Centre hospitalier Métropole de Savoie - Chambéry - France | Contact (sur clinicalTrials) | ||||
| CH Bretagne Atlantique - Vannes - France | Contact (sur clinicalTrials) | ||||
| CH d'ANNECY - Annecy - France | Contact (sur clinicalTrials) | ||||
| CH de METZ - Metz - France | Contact (sur clinicalTrials) | ||||
| CH Dunkerque - Dunkerque - France | Contact (sur clinicalTrials) | ||||
| CH Perpignan - Perpignan - France | Contact (sur clinicalTrials) | ||||
| CHU Amiens Picardie - Amiens - France | Contact (sur clinicalTrials) | ||||
| CHU Bordeaux - 31400 - Bordeaux - France | Contact (sur clinicalTrials) | ||||
| CHU CAEN - Caen - France | Contact (sur clinicalTrials) | ||||
| CHU Clermont-Ferrand Site Estaing - Clermont Ferrand - France | Contact (sur clinicalTrials) | ||||
| CHU de Besançon - Besançon - France | Contact (sur clinicalTrials) | ||||
| CHU de Lille - Lille - France | Contact (sur clinicalTrials) | ||||
| Chu de Nantes - Nantes - France | Contact (sur clinicalTrials) | ||||
| CHU de Nice - Nice - France | Contact (sur clinicalTrials) | ||||
| Chu de Rennes - Rennes - France | Contact (sur clinicalTrials) | ||||
| CHU de Tours - Tours - France | Contact (sur clinicalTrials) | ||||
| Chu Dijon - Dijon - France | Contact (sur clinicalTrials) | ||||
| CHU Henri Mondor - Créteil - France | Contact (sur clinicalTrials) | ||||
| CHU Saint-Eloi - CHU de Montpellier - Montpellier - France | Contact (sur clinicalTrials) | ||||
| CHU Toulouse - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Groupe hospitalier Bretagne Sud - Lorient - France | Contact (sur clinicalTrials) | ||||
| Hopital de la cote Basque - Bayonne - France | Contact (sur clinicalTrials) | ||||
| Hopital saint louis - Paris - France | Contact (sur clinicalTrials) | ||||
| Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne - Saint Priest-en-Jarez - France | Contact (sur clinicalTrials) | ||||
| Institut de Cancérologie Strasbourg Europe - Strasbourg - France | Contact (sur clinicalTrials) | ||||
| Institut Paoli Calmette - Marseille - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Adult patient (≥18 years) with multiple myeloma who will receive at least one dose
of teclistamab (first dose of the step-up dose)
- Adult patient (≥18 years) with multiple myeloma who will receive at least one dose
of teclistamab (first dose of the step-up dose)
- Patients alive at the start of the study who did not receive study information or
who objected to the collection of data
- Patients who received teclistamab as part of an interventional clinical trial
- Patients who are initiating teclistamab as part of a current interventional clinical
trial